查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2102785

CRISPR技術市場－2026年至2032年全球市場預測

CRISPR Technology Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，CRISPR 技術市場將成長至 103.2 億美元，複合年成長率為 14.41%。

主要市場統計數據
基準年 2025 40.2億美元
預計年份：2026年 45.7億美元
預測年份 2032 103.2億美元
複合年成長率 (%) 14.41%

CRISPR技術執行摘要

CRISPR技術已從實驗室發現平台發展成為重塑生物醫學研究、農業、工業生物技術和公共衛生的基礎基因組編輯技術。基於可程式設計核酸酶和引導RNA系統，CRISPR能夠以日益精準、快速且擴充性的方式對DNA和RNA進行標靶修飾。其應用範圍涵蓋體外和體內基因編輯、功能基因體學、細胞治療工程、感染疾病診斷、作物表現型改良、微生物菌株最佳化以及疾病模型建構。鹼基編輯、先導編輯、表觀基因編輯、CRISPR篩檢、遞送載體和高通量定序等方面的進步進一步推動了該領域的發展。一些重要的科學和監管里程碑，例如在主要司法管轄區批准基於CRISPR的遺傳性血液疾病療法，表明基因組編輯已進入具有臨床和轉化意義的新階段。同時，監管機構和倫理委員會正在加強對安全性、種系編輯、脫靶效應、公平取得和長期監測等方面的監管。因此，CRISPR 技術正成為生命科學整體研究機構、醫療保健系統、生物技術開發商、農業創新者和政策制定者的戰略重點，他們都在尋求更準確、更永續和擴充性的解決方案。

CRISPR領域的變革性變化

隨著業界從傳統的基因敲除方法轉向更複雜的編輯技術，CRISPR技術領域正經歷著變革性的轉變。鹼基編輯器和先導編輯器正在擴展其功能，能夠在不造成雙鏈的情況下糾正單核苷酸突變，而CRISPR活化和干擾工具則實現了可逆的基因控制，從而應用於功能基因組學和治療藥物的發現。遞送方法仍然是關鍵的差異化因素，脂質奈米顆粒、病毒載體、人工類病毒顆粒、電穿孔和組織靶向製劑等技術正在不斷改進，以提高編輯效率並降低安全風險。在臨床研究方面，研究重點正從罕見的單基因疾病轉向更廣泛的治療領域，例如腫瘤學、血液學、免疫學、眼科學、心血管疾病和感染疾病。在農業領域，CRISPR正在加速培育具有氣候變遷適應性、營養價值更高、抗病性更強以及減少投入依賴性的性狀。法規環境也在發生變化，一些司法管轄區將某些基因編輯生物體與傳統的基因改造生物體區分開來，前提是基因編輯過程中沒有引入外源DNA。這些變化表明，生態系統日趨成熟，更加重視準確性、安全性、可重複性、透明的風險評估和實際應用。

人工智慧對CRISPR技術的累積影響

人工智慧透過改進引導RNA設計、脫靶預測、蛋白質工程、遞送方法最佳化以及多體學分析的解讀，進一步增強了CRISPR技術的影響力。基於基因組、轉錄組、表觀基因和篩檢資料集訓練的機器學習模型，有助於識別功能性基因靶點，並優先選擇具有高度生物學相關性的編輯策略。人工智慧驅動的設計工具正被擴大用於開發下一代核酸酶，這些核酸酶能夠預測引導RNA活性、減少非預期編輯、修改原間隔序列鄰近基序的要求、提高保真度，或具有適合藥物遞送限制的緊湊結構。在藥物發現領域，人工智慧驅動的CRISPR篩檢分析可以闡明合成致死交互作用、抗藥性機制和通路依賴性，尤其是在腫瘤學和罕見疾病研究中。在農業和工業生物技術領域，人工智慧透過整合大規模生物資料集中的基因型-表現型關係，支持性狀基因的發現和菌株工程。然而，隨著對人工智慧的依賴性增加，對透明的模型檢驗、具有代表性的資料集、網路安全的生物資訊學流程、可審計的數據管治以及嚴格的實驗檢驗的需求也隨之增加，以確保計算預測能夠帶來可靠的基因組編輯結果。

關於 CRISPR 技術的關鍵區域見解

亞太地區正迅速崛起為CRISPR技術領域的活躍區域，這得益於不斷擴展的基因組基礎設施、政府主導的生物技術舉措、農業生物技術項目以及中國、日本、韓國、印度、新加坡和澳大利亞等國強大的學術研究實力。該地區的優先發展領域包括作物改良、精準醫療、感染疾病著成熟的生物醫學研究資金、臨床試驗基礎設施、先進的定序能力以及在基因和細胞治療領域強力的監管參與（包括評估基因組編輯安全性、生產品質和長期隨訪的正式框架），仍然是CRISPR研究實際應用的重要中心。在拉丁美洲，CRISPR技術的實用化正在擴展到農業、熱帶疾病研究、生物多樣性研究和公共衛生診斷領域，其中巴西和墨西哥在科學能力建設和作物相關研究方面發揮關鍵作用。歐洲擁有高度結構化的科學和倫理管治環境，並在基因組醫學、植物科學和功能基因組學領域進行活躍的研究。然而，隨著關於新型基因組技術的政策討論不斷深入，關於基因編輯作物及其環境應用的監管辯論仍在繼續。在中東，對基因組學、精準醫療、糧食安全和研究夥伴關係的投資正在增加，尤其是在那些優先考慮醫療現代化、國家基因組學舉措和農業韌性的國家。在非洲，CRISPR技術的應用與感染疾病診斷、作物韌性、糧食安全和當地科研能力密切相關，因此更加重視公平的技術轉移、生物安全框架、區域疾病控制重點和在地化農業創新。

CRISPR技術的關鍵群體分析

東南亞國協正透過投資生物醫學研究、農業創新、感染疾病監測和學術合作，加強其CRISPR技術能力，其中新加坡作為基因組學、生物資訊學和轉化生物技術的區域中心發揮重要作用。海灣合作理事會（GCC）國家日益關注精準醫療、國家基因組計畫、糧食安全和醫療創新，這為在不斷發展的生物倫理和法律規範內開展CRISPR診斷、研究基礎設施建設和治療藥物開發創造了機會。歐盟管治集團，匯集了大規模的患者群體、農業需求、生物多樣性資源以及巴西、俄羅斯、印度、中國和南非不斷增強的生物技術能力。七國集團在研究經費、臨床應用、基因測序基礎設施和監管科學方面繼續發揮主導作用，並在製定CRISPR先進療法的安全、品質、倫理和監管方面的全球標準方面處於核心地位。北約成員國透過管治，間接為CRISPR的發展做出了貢獻。隨著基因組編輯工具的取得變得更加容易且更具戰略敏感性，它們的作用尤其重要。

主要國家在CRISPR技術方面的趨勢

美國是全球CRISPR技術研究、臨床應用、監管科學和生物技術開發的中心，積極參與基因治療、細胞治療、診斷和功能基因組學。加拿大透過其基因組研究網路、幹細胞科學、農業生物技術和負責任的創新框架做出貢獻。墨西哥憑藉其日益成長的學術實力，正在提升CRISPR技術在作物科學、生物醫學研究和公共衛生應用領域的重要性。巴西積極進行農業基因組編輯、熱帶疾病研究、畜牧業改良以及與生物多樣性相關的生物技術研究。英國在基因組學、臨床研究、罕見疾病科學以及與監管管治在基因編輯療法和精準醫療方面的合作方面擁有先進的能力。德國是分子生物學、工業生物技術、學術研究和醫學創新領域的重要貢獻者，而法國則專注於生物醫學研究、植物科學和倫理治理。俄羅斯在基因組編輯、生殖生物學和生物技術領域進行科學活動，並兼顧自身的監管和倫理考量。義大利和西班牙積極參與生物醫學研究、農業科學和歐洲聯合計畫。中國在醫學、農業、動物模型和生物技術領域的CRISPR研究取得了廣泛的成果，並著重加強轉化研究能力和管理體制。印度正積極推動CRISPR技術在農業、醫療保健、感染疾病研究和經濟適用型生物技術領域的應用，包括公共資助的基因編輯作物和診斷方法研究。日本以其高品質的監管科學而著稱，涵蓋再生醫學、精準醫學、作物研究以及針對特定基因編輯食品的成熟核准流程。澳洲透過農業韌性計畫、生物醫學研究、基因組分析基礎設施和生物安全專業知識支持CRISPR技術的發展，而韓國則在基因編輯工具、治療研究、幹細胞科學和先進生物技術製造領域積極開展工作。

為CRISPR行業領導者提供的實用建議

產業領導者應優先考慮將科學嚴謹性、監管準備、倫理管治和可擴展部署結合的CRISPR策略。首先，各機構應投資於高保真編輯系統、經驗證的引導RNA設計以及利用正交定序和功能分析進行可靠的脫靶檢驗。其次，遞送技術的創新應定位為核心策略能力，尤其是在體內治療、組織選擇性編輯和農業實用化。第三，領導者應將人工智慧驅動的藥物發現與實驗檢驗的工作流程結合，以改善標靶選擇、引導RNA設計和表現型解讀，同時避免過度依賴不透明的計算模型。第四，與監管機構的早期合作至關重要，尤其對於需要長期追蹤、生產控制、藥物安全監測計畫和臨床安全監測的治療應用。第五，各機構應建構透明的生物倫理和生物安全框架，以解決種系界線、雙重用途風險、環境釋放、病人知情同意、資料管治和公平取得等問題。第六，由學術機構、臨床網路、農業組織、標準化機構和公共衛生相關人員組成的合作模式可以加速負責任的實施。最後，由於各國在法規、保險報銷機制、作物核准流程、資料保護要求以及對CRISPR技術的社會接受度方面存在顯著差異，領導者應制定針對特定區域的商業化和合規策略。

調查方法

本執行摘要採用系統的二手研究方法編寫，檢驗關注從同行評審的科學文獻、監管出版刊物、公共衛生機構、專利和臨床研究註冊庫、政府生物技術戰略、農業生物安全資訊來源以及國際政策文件中獲取的經核實且有數據支持的資訊。調查方法過程強調跨獨立資訊來源進行檢驗，以檢驗科學趨勢、區域活動、調節方向和應用領域的相關性。研究特別關注CRISPR技術平台，包括基於核酸酶的編輯、鹼基編輯、先導編輯、表觀基因編輯、CRISPR診斷、功能基因組學篩檢和遞送系統。透過公開可取得的研究項目、政策框架、舉措計劃、臨床試驗活動、農業生物技術進展、倫理指南和科學基礎設施信息，評估了區域和國家層面的具體見解。本調查方法避免了不實的預測，因此不涉及市場規模、市場佔有率和預測數據。研究結果將進行定性解讀，以確定其對醫療保健、農業、工業生物技術、診斷、學術研究和公共政策等領域的相關人員的戰略意義。

結論

CRISPR技術正在重新定義基因組工程的邊界，使醫學、農業、診斷和生物技術領域能夠進行更精準、可程式設計且擴充性的干預。該領域正透過新一代編輯系統、改進的遞送方法、人工智慧驅動的設計以及不斷擴展的轉化研究而迅速發展，檢驗的臨床和農業應用案例也證明了其日益成長的實用價值。同時，負責任的技術開發需要嚴格的安全檢驗、透明的管治、監管協調、全面的生物安全保障以及公眾信任。區域能力正在多元化發展，北美、歐洲和亞太地區在科學和轉化研究方面處於領先地位，而拉丁美洲、中東和非洲則正在見證CRISPR技術在農業韌性、醫療保健、感染疾病控制和能力建設等方面的廣泛應用。那些能夠將卓越的技術、倫理遠見、資料完整性和區域特定策略相結合的組織，最有能力最大限度地發揮CRISPR技術的優勢，同時妥善應對其科學、社會和監管方面的複雜性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 CRISPR技術市場：依產品/服務分類

  • 產品
    • 酵素
    • 引導RNA
    • 試劑盒和試劑
  • 服務
    • 細胞株改造
    • gRNA設計與載體構建
    • 篩檢服務

第8章 CRISPR技術市場：以交付方式分類

  • Ex Vivo
    • 細胞株改造
    • 體外初代細胞修飾
  • 體內
    • 直接編輯
    • 奈米顆粒遞送
    • 重定向載體

第9章 CRISPR技術市場：按應用領域分類

  • 在農業領域的應用
    • 畜牧養殖
    • 抗蟲害
  • 生物醫學領域的應用
    • 藥物發現與開發
    • 基因治療
  • 診斷
  • 工業生物技術
    • 生質燃料生產
    • 微生物菌株的改造

第10章：CRISPR技術市場：依最終用戶分類

  • 學術研究機構
  • 生技公司
  • 受託研究機構
  • 製藥公司

第11章：CRISPR技術市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章：CRISPR技術市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章：CRISPR技術市場：按國家/地區分類

  • 美國
  • 德國
  • 中國
  • 英國
  • 印度
  • 日本
  • 俄羅斯
  • 巴西
  • 加拿大
  • 義大利
  • 墨西哥
  • 法國
  • 西班牙
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • AgBiome Inc.
  • Agilent Technologies, Inc.
  • BASF SE
  • Bayer AG
  • Beam Therapeutics Inc.
  • Benson Hill Biosystems, Inc.
  • Caribou Biosciences, Inc.
  • Cibus Inc.
  • CRISPR Therapeutics AG
  • Danaher Corporation
  • Editas Medicine, Inc.
  • GeneCopoeia, Inc.
  • Genscript Biotech Corporation
  • Hera BioLabs
  • Intellia Therapeutics Inc.
  • Lonza Group Ltd.
  • Mammoth Biosciences, Inc.
  • Merck KGaA
  • Pairwise Foods Inc.
  • Syngenta AG
  • Thermo Fisher Scientific, Inc.
  • ToolGen Inc,
  • Yield10 Bioscience, Inc.
Product Code: MRR-B1685377A648

The CRISPR Technology Market is projected to grow by USD 10.32 billion at a CAGR of 14.41% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.02 billion
Estimated Year [2026] USD 4.57 billion
Forecast Year [2032] USD 10.32 billion
CAGR (%) 14.41%

CRISPR Technology Executive Summary

CRISPR technology has moved from a laboratory discovery platform to a foundational genome-editing capability reshaping biomedical research, agriculture, industrial biotechnology, and public health. Built on programmable nucleases and guide RNA systems, CRISPR enables targeted modification of DNA and RNA with increasing precision, speed, and scalability. Its applications span ex vivo and in vivo gene editing, functional genomics, cell therapy engineering, infectious disease diagnostics, crop trait improvement, microbial strain optimization, and disease-model development. The field is being strengthened by advances in base editing, prime editing, epigenome editing, CRISPR screening, delivery vectors, and high-throughput sequencing. Verified scientific and regulatory milestones, including authorized CRISPR-based therapeutics for inherited blood disorders in major jurisdictions, demonstrate that genome editing has entered a new phase of clinical and translational relevance. Regulatory agencies and ethics bodies are simultaneously increasing oversight around safety, germline editing, off-target effects, equitable access, and long-term monitoring. As a result, CRISPR technology is becoming a strategic priority for research institutions, healthcare systems, biotechnology developers, agricultural innovators, and policy leaders seeking more precise, durable, and scalable solutions across life sciences.

Transformative Shifts in the CRISPR Landscape

The CRISPR technology landscape is undergoing transformative shifts as the industry moves beyond conventional gene knockout approaches toward more sophisticated editing modalities. Base editors and prime editors are expanding the ability to correct single-nucleotide variants without creating double-strand breaks, while CRISPR activation and interference tools are enabling reversible gene regulation for functional genomics and therapeutic discovery. Delivery remains a central differentiator, with lipid nanoparticles, viral vectors, engineered virus-like particles, electroporation, and tissue-targeted formulations being refined to improve editing efficiency and reduce safety risks. In clinical research, emphasis is shifting from rare monogenic disorders toward broader therapeutic areas, including oncology, hematology, immunology, ophthalmology, cardiovascular disease, and infectious diseases. In agriculture, CRISPR is accelerating trait development for climate resilience, nutritional quality, disease resistance, and reduced input dependency. The regulatory environment is also evolving, with several jurisdictions distinguishing certain gene-edited organisms from traditional genetically modified organisms when edits do not introduce foreign DNA. These shifts indicate a maturing ecosystem focused on precision, safety, reproducibility, transparent risk assessment, and real-world translational impact.

Cumulative Impact of Artificial Intelligence on CRISPR

Artificial intelligence is compounding the impact of CRISPR technology by improving guide RNA design, off-target prediction, protein engineering, delivery optimization, and multi-omics interpretation. Machine learning models trained on genomic, transcriptomic, epigenomic, and screening datasets help identify functional genetic targets and prioritize edit strategies with higher likelihood of biological relevance. AI-assisted design tools are increasingly used to predict guide RNA activity, reduce unintended edits, and support the development of next-generation nucleases with altered protospacer adjacent motif requirements, improved fidelity, or compact structures suitable for delivery constraints. In drug discovery, AI-enabled CRISPR screening analytics can reveal synthetic lethal interactions, resistance mechanisms, and pathway dependencies, particularly in oncology and rare disease research. In agriculture and industrial biotechnology, AI supports trait-gene discovery and strain engineering by integrating genotype-phenotype relationships across large biological datasets. However, the growing reliance on AI also increases the need for transparent model validation, representative datasets, cybersecure bioinformatics pipelines, auditable data governance, and rigorous experimental confirmation to ensure that computational predictions translate into reliable genome-editing outcomes.

Key Regional Insights Across CRISPR Technology

Asia-Pacific is emerging as a highly active CRISPR technology region, supported by expanding genomics infrastructure, government-backed biotechnology initiatives, agricultural biotechnology programs, and strong academic research in China, Japan, South Korea, India, Singapore, and Australia. The region's priorities include crop improvement, precision medicine, infectious disease research, and scalable biomanufacturing, with regulatory approaches varying widely by jurisdiction. North America remains a major center for CRISPR research translation, supported by established biomedical research funding, clinical trial infrastructure, advanced sequencing capabilities, and strong regulatory engagement around gene and cell therapies, including formal frameworks for evaluating genome-editing safety, manufacturing quality, and long-term follow-up. Latin America is increasingly applying CRISPR technology to agriculture, tropical disease research, biodiversity studies, and public health diagnostics, with Brazil and Mexico playing important roles in scientific capacity building and crop-related research. Europe maintains a highly structured scientific and ethical governance environment, with robust research activity in genome medicine, plant science, and functional genomics, while regulatory debate continues around gene-edited crops and environmental applications under evolving policy discussions on new genomic techniques. The Middle East is investing in genomics, precision health, food security, and research partnerships, particularly in countries prioritizing healthcare modernization, national genome initiatives, and agricultural resilience. Africa's CRISPR technology adoption is closely linked to infectious disease diagnostics, crop resilience, food security, and local scientific capacity, with growing emphasis on equitable technology transfer, biosafety frameworks, regional disease priorities, and context-specific agricultural innovation.

Key Group Insights Across CRISPR Technology

ASEAN countries are strengthening CRISPR technology capabilities through investments in biomedical research, agricultural innovation, infectious disease surveillance, and academic collaborations, with Singapore serving as a regional hub for genomics, bioinformatics, and translational biotechnology. The GCC is increasingly focused on precision medicine, national genome programs, food security, and healthcare innovation, creating opportunities for CRISPR-enabled diagnostics, research infrastructure, and therapeutic development under evolving bioethics and regulatory frameworks. The European Union remains influential in shaping CRISPR governance through harmonized research standards, clinical regulation, data protection rules, and ongoing policy discussions on new genomic techniques in agriculture, with strong emphasis on environmental safety, traceability, and public consultation. BRICS economies represent a diverse but strategically important CRISPR technology grouping, combining large patient populations, agricultural needs, biodiversity resources, and expanding biotechnology capacity in Brazil, Russia, India, China, and South Africa. The G7 countries continue to lead in research funding, clinical translation, genome sequencing infrastructure, and regulatory science, making them central to global standards for CRISPR safety, quality, ethics, and advanced therapy oversight. NATO member countries contribute indirectly to CRISPR development through biosecurity policy, advanced life science research, public health preparedness, and dual-use research governance, particularly as genome-editing tools become more accessible and strategically sensitive.

Key Country Insights Across CRISPR Technology

The United States is a global center for CRISPR technology research, clinical translation, regulatory science, and biotechnology development, with strong activity in gene therapy, cell therapy, diagnostics, and functional genomics. Canada contributes through genomics research networks, stem cell science, agricultural biotechnology, and responsible innovation frameworks. Mexico is building CRISPR relevance in crop science, biomedical research, and public health applications, supported by growing academic expertise. Brazil is active in agricultural genome editing, tropical disease research, livestock improvement, and biodiversity-related biotechnology. The United Kingdom has advanced capabilities in genomics, clinical research, rare disease science, and regulatory engagement for gene-editing therapies and precision medicine. Germany is a major contributor in molecular biology, industrial biotechnology, academic research, and medical innovation, while France emphasizes biomedical research, plant science, and ethics-driven governance. Russia has scientific activity in genome editing, reproductive biology, and biotechnology, alongside distinct regulatory and ethical considerations. Italy and Spain are active in biomedical research, agricultural science, and European collaborative programs. China has extensive CRISPR research output across medicine, agriculture, animal models, and biotechnology, with strong emphasis on translational capacity and regulatory strengthening. India is advancing CRISPR applications in agriculture, healthcare, infectious disease research, and affordable biotechnology, including publicly supported work on gene-edited crops and diagnostics. Japan is notable for regenerative medicine, precision therapeutics, crop research, and high-quality regulatory science, including established pathways for certain genome-edited foods. Australia supports CRISPR development through agricultural resilience programs, biomedical research, genomics infrastructure, and biosecurity expertise, while South Korea is active in gene-editing tools, therapeutics research, stem cell science, and advanced biotechnology manufacturing.

Actionable Recommendations for CRISPR Industry Leaders

Industry leaders should prioritize CRISPR strategies that combine scientific rigor, regulatory readiness, ethical governance, and scalable deployment. First, organizations should invest in high-fidelity editing systems, validated guide RNA design, and robust off-target assessment using orthogonal sequencing and functional assays. Second, delivery innovation should be treated as a core strategic capability, particularly for in vivo therapies, tissue-selective editing, and agricultural field performance. Third, leaders should integrate AI-enabled discovery with experimentally validated workflows to improve target selection, guide design, and phenotype interpretation while avoiding overreliance on opaque computational models. Fourth, early regulatory engagement is essential, especially for therapeutic applications requiring long-term follow-up, manufacturing controls, pharmacovigilance planning, and clinical safety monitoring. Fifth, organizations should build transparent bioethics and biosafety frameworks that address germline boundaries, dual-use risks, environmental release, patient consent, data governance, and equitable access. Sixth, collaborative models involving academic institutions, clinical networks, agricultural agencies, standards bodies, and public health stakeholders can accelerate responsible adoption. Finally, leaders should develop region-specific commercialization and compliance strategies because CRISPR regulation, reimbursement pathways, crop approval processes, data protection requirements, and public acceptance differ significantly across countries.

Research Methodology

This executive summary is developed through a structured secondary-research methodology focused on verified, data-backed information from peer-reviewed scientific literature, regulatory publications, public health authorities, patent and clinical research registries, government biotechnology strategies, agricultural biosafety sources, and international policy documentation. The research process emphasizes triangulation across independent sources to validate scientific trends, regional activity, regulatory direction, and application areas. Particular attention is given to CRISPR technology platforms, including nuclease-based editing, base editing, prime editing, epigenome editing, CRISPR diagnostics, functional genomics screening, and delivery systems. Regional and country insights are assessed through publicly available evidence of research programs, policy frameworks, genomics initiatives, clinical trial activity, agricultural biotechnology developments, ethics guidance, and scientific infrastructure. The methodology avoids unsupported projections and excludes market sizing, market share, and forecasting. Insights are interpreted through a qualitative lens to identify strategic implications for stakeholders in healthcare, agriculture, industrial biotechnology, diagnostics, academic research, and public policy.

Conclusion

CRISPR technology is redefining the boundaries of genome engineering by enabling more precise, programmable, and scalable interventions across medicine, agriculture, diagnostics, and biotechnology. The field is progressing rapidly through next-generation editing systems, improved delivery methods, AI-assisted design, and expanding translational research, while validated clinical and agricultural use cases demonstrate growing practical relevance. At the same time, responsible advancement depends on rigorous safety validation, transparent governance, regulatory alignment, biosafety discipline, and public trust. Regional capabilities are diversifying, with North America, Europe, and Asia-Pacific driving substantial scientific and translational momentum, while Latin America, the Middle East, and Africa expand CRISPR applications aligned with agricultural resilience, healthcare access, infectious disease control, and capacity building. Organizations that combine technical excellence with ethical foresight, data integrity, and region-specific strategy will be best positioned to unlock the benefits of CRISPR technology while managing its scientific, societal, and regulatory complexities.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. CRISPR Technology Market, by Offering

  • 7.1. Introduction
  • 7.2. Product
    • 7.2.1. Enzymes
    • 7.2.2. Guide RNA
    • 7.2.3. Kits & Reagents
  • 7.3. Services
    • 7.3.1. Cell Line Engineering
    • 7.3.2. gRNA Design & Vector Construction
    • 7.3.3. Screening Services

8. CRISPR Technology Market, by Delivery Method

  • 8.1. Introduction
  • 8.2. Ex Vivo
    • 8.2.1. Cell Line Modification
    • 8.2.2. Primary Cell Modification
  • 8.3. In Vivo
    • 8.3.1. Direct Editing
    • 8.3.2. Nanoparticle Delivery
    • 8.3.3. Retargeting Vectors

9. CRISPR Technology Market, by Application

  • 9.1. Introduction
  • 9.2. Agricultural Applications
    • 9.2.1. Livestock Breeding
    • 9.2.2. Pest Resistance
  • 9.3. Biomedical Applications
    • 9.3.1. Drug Discovery & Development
    • 9.3.2. Gene Therapy
  • 9.4. Diagnostics
  • 9.5. Industrial Biotechnology
    • 9.5.1. Biofuel Production
    • 9.5.2. Microbial Strain Engineering

10. CRISPR Technology Market, by End-User

  • 10.1. Introduction
  • 10.2. Academic & Research Institutes
  • 10.3. Biotech Companies
  • 10.4. Contract Research Organizations
  • 10.5. Pharmaceutical Companies

11. CRISPR Technology Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. CRISPR Technology Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. CRISPR Technology Market, by Country

  • 13.1. United States
  • 13.2. Germany
  • 13.3. China
  • 13.4. United Kingdom
  • 13.5. India
  • 13.6. Japan
  • 13.7. Russia
  • 13.8. Brazil
  • 13.9. Canada
  • 13.10. Italy
  • 13.11. Mexico
  • 13.12. France
  • 13.13. Spain
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2025
  • 14.2. FPNV Positioning Matrix, 2025
  • 14.3. Market Concentration Analysis, 2025
    • 14.3.1. Concentration Ratio (CR)
    • 14.3.2. Herfindahl Hirschman Index (HHI)
  • 14.4. Recent Developments & Impact Analysis, 2025
  • 14.5. Product Portfolio Analysis, 2025
  • 14.6. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. AgBiome Inc.
  • 15.2. Agilent Technologies, Inc.
  • 15.3. BASF SE
  • 15.4. Bayer AG
  • 15.5. Beam Therapeutics Inc.
  • 15.6. Benson Hill Biosystems, Inc.
  • 15.7. Caribou Biosciences, Inc.
  • 15.8. Cibus Inc.
  • 15.9. CRISPR Therapeutics AG
  • 15.10. Danaher Corporation
  • 15.11. Editas Medicine, Inc.
  • 15.12. GeneCopoeia, Inc.
  • 15.13. Genscript Biotech Corporation
  • 15.14. Hera BioLabs
  • 15.15. Intellia Therapeutics Inc.
  • 15.16. Lonza Group Ltd.
  • 15.17. Mammoth Biosciences, Inc.
  • 15.18. Merck KGaA
  • 15.19. Pairwise Foods Inc.
  • 15.20. Syngenta AG
  • 15.21. Thermo Fisher Scientific, Inc.
  • 15.22. ToolGen Inc,
  • 15.23. Yield10 Bioscience, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CRISPR TECHNOLOGY MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL CRISPR TECHNOLOGY MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL CRISPR TECHNOLOGY MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL CRISPR TECHNOLOGY MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL CRISPR TECHNOLOGY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 21. GLOBAL CRISPR TECHNOLOGY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL CRISPR TECHNOLOGY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PRODUCT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PRODUCT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PRODUCT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENZYMES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ENZYMES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENZYMES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GUIDE RNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GUIDE RNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GUIDE RNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL KITS & REAGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL KITS & REAGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL KITS & REAGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CELL LINE ENGINEERING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CELL LINE ENGINEERING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CELL LINE ENGINEERING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GRNA DESIGN & VECTOR CONSTRUCTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GRNA DESIGN & VECTOR CONSTRUCTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GRNA DESIGN & VECTOR CONSTRUCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SCREENING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SCREENING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SCREENING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL EX VIVO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL EX VIVO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL EX VIVO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CELL LINE MODIFICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CELL LINE MODIFICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CELL LINE MODIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PRIMARY CELL MODIFICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PRIMARY CELL MODIFICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PRIMARY CELL MODIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IN VIVO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IN VIVO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IN VIVO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DIRECT EDITING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DIRECT EDITING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DIRECT EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NANOPARTICLE DELIVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NANOPARTICLE DELIVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NANOPARTICLE DELIVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RETARGETING VECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RETARGETING VECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RETARGETING VECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL AGRICULTURAL APPLICATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL AGRICULTURAL APPLICATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL AGRICULTURAL APPLICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL LIVESTOCK BREEDING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL LIVESTOCK BREEDING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL LIVESTOCK BREEDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PEST RESISTANCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PEST RESISTANCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PEST RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIOMEDICAL APPLICATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOMEDICAL APPLICATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIOMEDICAL APPLICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DRUG DISCOVERY & DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DRUG DISCOVERY & DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DRUG DISCOVERY & DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL INDUSTRIAL BIOTECHNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL INDUSTRIAL BIOTECHNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL INDUSTRIAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOFUEL PRODUCTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BIOFUEL PRODUCTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOFUEL PRODUCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MICROBIAL STRAIN ENGINEERING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MICROBIAL STRAIN ENGINEERING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MICROBIAL STRAIN ENGINEERING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOTECH COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BIOTECH COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOTECH COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC CRISPR TECHNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST CRISPR TECHNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN CRISPR TECHNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 180. GCC CRISPR TECHNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. GCC CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 182. GCC CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 183. GCC CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 184. GCC CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 185. GCC CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 186. GCC CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 187. GCC CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. GCC CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 189. GCC CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 190. GCC CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. GCC CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION CRISPR TECHNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS CRISPR TECHNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 216. G7 CRISPR TECHNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 217. G7 CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 218. G7 CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 219. G7 CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 220. G7 CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 221. G7 CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 222. G7 CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 223. G7 CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 224. G7 CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 225. G7 CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 226. G7 CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 227. G7 CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 228. NATO CRISPR TECHNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 229. NATO CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 230. NATO CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 231. NATO CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 232. NATO CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 233. NATO CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 234. NATO CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 235. NATO CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 236. NATO CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 237. NATO CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 238. NATO CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 239. NATO CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 253. GERMANY CRISPR TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. GERMANY CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 255. GERMANY CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 256. GERMANY CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 257. GERMANY CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 258. GERMANY CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 259. GERMANY CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 260. GERMANY CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 261. GERMANY CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 262. GERMANY CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 263. GERMANY CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 264. GERMANY CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA CRISPR TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED KINGDOM CRISPR TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED KINGDOM CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED KINGDOM CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED KINGDOM CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED KINGDOM CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED KINGDOM CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED KINGDOM CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED KINGDOM CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED KINGDOM CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED KINGDOM CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED KINGDOM CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED KINGDOM CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 289. INDIA CRISPR TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 290. INDIA CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 291. INDIA CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 292. INDIA CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 293. INDIA CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 294. INDIA CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 295. INDIA CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 296. INDIA CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 297. INDIA CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 298. INDIA CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 299. INDIA CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 300. INDIA CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 301. JAPAN CRISPR TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 302. JAPAN CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 303. JAPAN CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 304. JAPAN CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 305. JAPAN CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 306. JAPAN CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 307. JAPAN CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 308. JAPAN CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 309. JAPAN CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 310. JAPAN CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 311. JAPAN CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 312. JAPAN CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 313. RUSSIA CRISPR TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 314. RUSSIA CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 315. RUSSIA CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 316. RUSSIA CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 317. RUSSIA CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 318. RUSSIA CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 319. RUSSIA CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 320. RUSSIA CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 321. RUSSIA CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 322. RUSSIA CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 323. RUSSIA CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 324. RUSSIA CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 325. BRAZIL CRISPR TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 326. BRAZIL CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 327. BRAZIL CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 328. BRAZIL CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 329. BRAZIL CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 330. BRAZIL CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 331. BRAZIL CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 332. BRAZIL CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 333. BRAZIL CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 334. BRAZIL CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 335. BRAZIL CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 336. BRAZIL CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 337. CANADA CRISPR TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 338. CANADA CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 339. CANADA CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 340. CANADA CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 341. CANADA CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 342. CANADA CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 343. CANADA CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 344. CANADA CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 345. CANADA CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 346. CANADA CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 347. CANADA CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 348. CANADA CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 349. ITALY CRISPR TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 350. ITALY CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 351. ITALY CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 352. ITALY CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 353. ITALY CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 354. ITALY CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 355. ITALY CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 356. ITALY CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 357. ITALY CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 358. ITALY CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 359. ITALY CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 360. ITALY CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 361. MEXICO CRISPR TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 362. MEXICO CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 363. MEXICO CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 364. MEXICO CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 365. MEXICO CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 366. MEXICO CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 367. MEXICO